Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma
Cancer Cell · 2024-12 · 42 (12) · 2082-2097.e10
DOI: 10.1016/j.ccell.2024.10.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024-12. Verfasst von Chun-Xiang Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Su…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, T-Lymphocytes, Cytotoxic, Immunotherapy. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Guangdong Provincial Natural Science Foundation, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Hyperprogressive disease can occur in cancer patients receiving immune checkpoint blockade (ICB) therapy, but whether and how reactive cytotoxic T lymphocytes (CTLs) exert protumorigenic effects in this context remain elusive. Herein, our study reveals that pericancerous macrophages cross-present antigens to CD103+ CTLs in hepatocellular carcinoma (HCC) via the endoplasmic reticulum (ER)-associated degradation machinery-mediated cytosolic pathway. This process leads to the retention of CD103+ CTLs in the pericancerous area, whereby they activate NLRP3 inflammasome in macrophages, promoting hepatoma progression and resistance to immunotherapy. Our single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics analysis of HCC patients shows that despite their tissue-resident effector phenotype, the aggregation of CD103+ CTLs predicts unfavorable clinical outcomes for HCC patients receiving multiple types of treatment. Correspondingly, therapeutic strategies that redistribute CD103+ CTLs can disrupt this pathogenic interplay with macrophages, enhancing the efficacy of ICB treatment against HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Department of Hepatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
- Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China; Innovation Center of th…
Förderung
- Guangdong Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Huang, C. X., Lao, X. M., Wang, X. Y., Ren, Y. Z., Lu, Y. T., Shi, W., Wang, Y. Z., Wu, C. Y., Xu, L., Chen, M. S., Gao, Q., Liu, L., Wei, Y., & Kuang, D. M. (2024). Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell, 42(12), 2082-2097.e10. https://doi.org/10.1016/j.ccell.2024.10.012
Vancouver
Huang CX, Lao XM, Wang XY, Ren YZ, Lu YT, Shi W, et al. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell. 2024;42(12):2082-2097.e10. doi:10.1016/j.ccell.2024.10.012
BibTeX
@article{Huang2024,
author = {Huang, Chun-Xiang and Lao, Xiang-Ming and Wang, Xu-Yan and Ren, Yi-Zheng and Lu, Yi-Tong and Shi, Wei and Wang, Ying-Zhe and Wu, Cai-Yuan and Xu, Li and Chen, Min-Shan and Gao, Qiang and Liu, Lianxin and Wei, Yuan and Kuang, Dong-Ming},
title = {Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {12},
pages = {2082--2097.e10},
doi = {10.1016/j.ccell.2024.10.012}
}
EUVIMED